InvestorsHub Logo
Followers 36
Posts 1166
Boards Moderated 0
Alias Born 03/07/2013

Re: None

Monday, 10/31/2016 1:44:46 PM

Monday, October 31, 2016 1:44:46 PM

Post# of 118384
What did today's PR tell us that we didn't already know? Find the answer to that and you might find the reason for the PR.

My take:

"In lay terminology, the Company is looking to compile more supporting data as it conducts more experiments.



Meaning: We are still a long ways off, not days or weeks, but months or years to get where we want and need to be to conduct clinical trials.

"Regen BioPharma's management team believes in both the social and financial value of its small molecule program involving NR2F6. Since January 2015, we have raised more than $3.2 million to move things forward. This money has come from high net worth individuals that believe in the merits of the Company's research.
Looking ahead, we anticipate a combination of continued investment by high net worth individuals, transitioning to partnering arrangements with one or more larger pharmaceutical companies to assist us with clearing clinical trials," stated the Company's Chairman and CEO.



Meaning: We are continuing our F&F share plan, so don't be surprised when next financials show more money raised with .02-.05 shares being issued to company insiders. We are still a long ways away from being able to sign a contract with a pharmaceutical company for licensing or underwriting our research, but one day we hope to get there. Meanwhile they are asking for a lot more data and proof of concept before they are willing to sign on the dotted line.